信迪利单抗对复发性非小细胞肺癌的疗效研究

Therapeutic effect of Sintilimab on recurrent non-small cell lung cancer

目的:研究信迪利单抗对复发性非小细胞肺癌(R-NSCLC)的疗效。方法:回顾性分析2020年1月-2023年1月我院收治的153例R-NSCLC患者临床资料,按照治疗方案分为信迪利单抗联合化疗(实验组)79例和单纯化疗(对照组)74例。对照组患者第1天给予顺铂50 mg·m^(-2)静脉滴注,第2天或第3天给予吉西他滨1000 mg·m^(-2)静脉滴注,实验组患者在对照组基础上第1天给予信迪利单抗200 mg静脉滴注治疗。两组患者均以21 d为1疗程,治疗4个疗程。比较两组治疗后的临床疗效、血清肿瘤标志物水平、免疫功能和治疗安全性。结果:实验组客观缓解率和疾病控制率均较对照组高(65.82%vs 50.00%,93.67%vs 82.43%,P<0.05)。两组患者治疗后CYFRA21-1、CEA、CA199水平均较化疗前降低,且实验组低于对照组(P<0.05)。化疗后两组患者外周血CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均较化疗前升高,且实验组水平均较对照组高(P<0.05);两组患者化疗前、后CD8+水平差异无统计学意义(P>0.05)。两组患者治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。结论:信迪利单抗可提高R-NSCLC患者治疗效果,调节机体免疫功能,降低患者血清肿瘤标志物水平。

Objective:To investigate the therapeutic efficacy of sintilimab for recurrent non-small cell lung cancer(R-NSCLC).Methods:The clinical data of 153 patients with R-NSCLC admitted to our hospital from January 2019 to January 2019 were retrospectively analyzed.Patients were assigned into two groups according to different treatment plans.The patients in control group(n=74)recieved intravenous infusion of cisplatin 50 mg·m^(-2)on day 1 and that of gemcitabine 1000 mg·m^(-2)on day 2 or 3.The patients in the experimental group undergoing intravenous infustion of sintilimab 200 mg on day 1 in addition to that in the control group.All patients were treated for 4 courses of treatment with 21d as 1 course.Then the clinical efficacy,serum tumour markers,immune function and treatment safety were compared between the 2groups.Results:Experimental group reported a higher objective remission rate and disease control rate as compared to control one(65.82%vs.50.00%,93.67%vs.82.43%,P<0.05).A reduction in cytokeratin fragment 19(CYFRA 21-1),carcinoembryonic antigen(CEA)and carbohydrate antigen 199(CA199),and an increase in peripheral blood CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were observed in all patients after treatment,and both improvements were more notable in the experimental group than in the control(P<0.05).No statistical difference was reported in CD8^(+) before and after chemotherapy between the 2 groups(P>0.05).The incidence of adverse reactions during treatment yielded no statistical difference between the 2 groups(P>0.05).Conclusion:Sintilimab is effective in treating patients with R-NSCLC,which can improve patients'immune function and significantly reduce serum levels of tumour markers.